Exendin-4 promotes endothelial barrier enhancement via PKA- and Epac1-dependent Rac1 activation

American Journal of Physiology - Cell Physiology

Volumn 308, Issue 2, 2015, Pages C164-C175

  Li, Ai Q ^a   Zhao, Liang ^a   Zhou, Teng F ^a   Zhang, Meng Q ^a   Qin, Xiao M ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Protein kinase A; Rac1; VE cadherin

Indexed keywords

CYCLIC AMP; EPAC1 PROTEIN; EXENDIN 4; F ACTIN; GLUCAGON LIKE PEPTIDE 1; GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAC1 PROTEIN; SMALL INTERFERING RNA; THROMBIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; ACTIN; CADHERIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LEUKOCYTE ANTIGEN; PEPTIDE; VENOM;

AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; PKA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VASCULAR DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CAPILLARY PERMEABILITY; CELL CULTURE; MALE; METABOLISM; MOUSE; PHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

MUS;

ACTINS; ANIMALS; ANTIGENS, CD; CADHERINS; CAPILLARY PERMEABILITY; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DEXTRANS; ENDOTHELIAL CELLS; FLUORESCEIN-5-ISOTHIOCYANATE; GLUCAGON-LIKE PEPTIDE 1; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; PEPTIDES; RAC1 GTP-BINDING PROTEIN; RECEPTORS, GLUCAGON; THROMBIN; VENOMS;

EID: 84921526700     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00249.2014     Document Type: Article

References (49)

1. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59: 1030–1037, 2010.
2. Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, Miura D, Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis 232: 156–164, 2014.
3. Baumer Y, Spindler V, Werthmann RC, Bünemann M, Waschke J. Role of Rac 1 and cAMP in endothelial barrier stabilization and thrombin-induced barrier breakdown. J Cell Physiol 220: 716–726, 2009.
4. Birukova AA, Burdette D, Moldobaeva N, Xing J, Fu P, Birukov KG. Rac GTPase is a hub for protein kinase A and Epac signaling in endothe-lial barrier protection by cAMP. Microvasc Res 79: 128–138, 2010.
5. Birukova AA, Zagranichnaya T, Fu P, Alekseeva E, ChenW, Jacob-son JR, Birukov KG. Prostaglandins PGE2 and PGI2 promote endothe-lial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Exp Cell Res 313: 2504–2520, 2007.
6. Bubik MF, Willer EA, Bihari P, Jürgenliemk G, Ammer H, Krom-bach F, Zahler S, Vollmar AM, Fürst R. A novel approach to prevent endothelial hyperpermeability: the Crataegus extract WS® 1442 targets the cAMP/Rap1 pathway. J Mol Cell Cardiol 52: 196–205, 2012.
7. Curry FR, Adamson RH. Vascular permeability modulation at the cell, microvessel, or whole organ level: towards closing gaps in our knowledge. Cardiovasc Res 87: 218–229, 2010.
8. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 5: 261–270, 2004.
9. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 16: 209–221, 2009.
10. Di Lorenzo A, Lin MI, Murata T, Landskroner-Eiger S, Schleicher M, Kothiya M, Iwakiri Y, Yu J, Huang PL, Sessa WC. eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. J Cell Sci 126: 5541–5552, 2013.
11. Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, Kapiloff MS, Scott JD. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437: 574–578, 2005.
12. Dokken BB, Piermarini CV, Teachey MK, Gura MT, Dameff CJ, Heller BD, Krate J, Ashgar AM, Querin L, Mitchell JL, Hilwig RW, Kern KB. Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential anti-oxidant effects. Am J Physiol Heart Circ Physiol 304: H538–H546, 2013.
13. Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 30: 1735–1741, 2009.
14. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 30: 609–624, 2010.
15. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62: 3316–3323, 2013.
16. Essler M, Amano M, Kruse HJ, Kaibuchi K, Weber PC, Aepfelbacher M. Thrombin inactivates myosin light chain phosphatase via Rho and its target Rho kinase in human endothelial cells. J Biol Chem 273: 21867–21874, 1998.
17. Fan Y, Liu K, Wang Q, Ruan Y, Ye W, Zhang Y. Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res 127C: 104–116, 2014.
18. Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M, Wilhelm B, Pfützner A. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabetes Med 29: 1115–1118, 2012.
19. Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin 30: 431–445, 2014.
20. Gulino-Debrac D. Mechanotransduction at the basis of endothelial barrier function (Abstract). Tissue Barriers 1: e24180, 2013.
21. Harris ES, Nelson WJ. VE-cadherin: at the front, center, and sides of endothelial cell organization and function. Curr Opin Cell Biol 22: 651–658, 2010.
22. Hatanaka K, Simons M, Murakami M. Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation. Am J Physiol Heart Circ Physiol 300: H162–H172, 2011.
23. Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, Gnasso A. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 10: 72–77, 2013.
24. Kobayashi K, Tsubosaka Y, Hori M, Narumiya S, Ozaki H, Murata T. Prostaglandin D2-DP signaling promotes endothelial barrier function via the cAMP/PKA/Tiam1/Rac1 pathway. Arterioscler Thromb Vasc Biol 33: 565–571, 2013.
25. Komarova Y, Malik AB. Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annu Rev Physiol 72: 463–493, 2010.
26. Lee W, Ku SK, Park EJ, Na DH, Kim KM, Bae JS. Exendin-4 inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis. Inflammation In press.
27. Lorenowicz MJ, Fernandez-Borja M, Hordijk PL. cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 27: 1014–1022, 2007.
28. Lum H, Jaffe HA, Schulz IT, Masood A, RayChaudhury A, Green RD. Expression of PKA inhibitor (PKI) gene abolishes cAMP-mediated protection to endothelial barrier dysfunction. Am J Physiol Cell Physiol 277: C580–C588, 1999.
29. Makarenko VV, Usatyuk PV, Yuan G, Lee MM, Nanduri J, Natara-jan V, Kumar GK, Prabhakar NR. Intermittent hypoxia-induced endo-thelial barrier dysfunction requires ROS-dependent MAP kinase activation. Am J Physiol Cell Physiol 306: C745–C752, 2014.
30. Mei FC, Qiao J, Tsygankova OM, Meinkoth JL, Quilliam LA, Cheng X. Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J Biol Chem 277: 11497–11504, 2002.
31. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962–965, 2004.
32. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ, Husain M. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127: 74–85, 2013.
33. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 30: 1407–1414, 2010.
34. Orsenigo F, Giampietro C, Ferrari A, Corada M, Galaup A, Sigis-mund S, Ristagno G, Maddaluno L, Koh GY, Franco D, Kurtcuoglu V, Poulikakos D, Baluk P, McDonald D, Grazia Lampugnani M, Dejana E. Phosphorylation of VE-cadherin is modulated by haemody-namic forces and contributes to the regulation of vascular permeability in vivo (Abstract). Nat Commun 3: 1208, 2012.
35. Peacock JG, Miller AL, Bradley WD, Rodriguez OC, Webb DJ, Koleske AJ. The Abl-related gene tyrosine kinase acts through p190RhoGAP to inhibit actomyosin contractility and regulate focal adhesion dynamics upon adhesion to fibronectin. Mol Biol Cell 18: 3860–3872, 2007.
36. Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence (Abstract). Cardiovasc Diabetol 12: 130, 2013.
37. Piotrowski K, Becker M, Zugwurst J, Biller-Friedmann I, Spoettl G, Greif M, Leber AW, Becker A, Laubender RP, Lebherz C, Goeke B, Marx N, Parhofer KG, Lehrke M. Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans (Abstract). Car-diovasc Diabetol 12: 117, 2013.
38. Qin X, Wang X, Wang Y, Tang Z, Cui Q, Xi J, Chien S, Wang N. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci USA 107: 3240–3244, 2010.
39. Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, Gribble FM, Reimann F. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63: 1224-1233, 2014.
40. Schlegel N, Waschke J. cAMP with other signaling cues converges on Rac1 to stabilize the endothelial barrier-a signaling pathway compromised in inflammation. Cell Tissue Res 355: 587-596, 2014.
41. Semina EV, Rubina KA, Sysoeva VY, Rutkevich PN, Kashirina NM, Tkachuk VA. Novel mechanism regulating endothelial permeability via T-cadherin-dependent VE-cadherin phosphorylation and clathrin-medi-ated endocytosis. Mol Cell Biochem 387: 39-53, 2014.
42. Sidibé A, Imhof BA. VE-cadherin phosphorylation decides: vascular permeability or diapedesis. Nat Immunol 15: 215-217, 2014.
43. Spindler V, Peter D, Harms GS, Asan E, Waschke J. Ultrastructural analysis reveals cAMP-dependent enhancement of microvascular endothelial barrier functions via Rac1-mediated reorganization of intercellular junctions. Am J Pathol 178: 2424-2436, 2011.
44. Tashiro Y, Sato K, Watanabe T, Nohtomi K, Terasaki M, Nagashima M, Hirano T. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 54C: 19-26, 2014.
45. Umapathy NS, Zemskov EA, Gonzales J, Gorshkov BA, Sridhar S, Chakraborty T, Lucas R, Verin AD. Extracellular ß-nicotinamide adenine dinucleotide (ß-NAD) promotes the endothelial cell barrier integrity via PKA- and EPAC1/Rac1-dependent actin cytoskeleton rearrangement. J Cell Physiol 223: 215-223, 2010.
46. Vandenbroucke B, St Amant E, Tauseef M, Vogel SM, Gao X, Mehta D, Komarova YA, Malik A. PKCa activation of p120-catenin serine 879 phospho-switch disassembles VE-cadherin junctions and disrupts vascular integrity Circ Res 111: 739-749, 2012.
47. Vestweber D, Winderlich M, Cagna G, Nottebaum AF. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol 19: 8-15, 2009.
48. Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, Wang H, Ren J, Cao F. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 62: 1697-1708, 2013.
49. Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, Jawad AH, Shiri-Sverdlov R, Bot I, de Jager SC, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PC. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol 171: 723-734, 2014.